THE SHAREHOLDERS’ MEETING OF LUMINEX CORPORATION APPROVED THE MERGER OF LUMINEX WITH A U.S. WHOLLY-OWNED SUBSIDIARY OF DIASORIN

Saluggia - June 21, 2021 - DiaSorin (FTSE MIB: DIA) announces that the Shareholders’ Meeting of Luminex Corporation (“Luminex”; NASDAQ: LMNX), held today, approved the merger of Luminex with a U.S. wholly-owned subsidiary of DiaSorin, pursuant to the merger agreement relating to the acquisition of Luminex by DiaSorin, as announced on April 11, 2021. Following the merger, Luminex shareholders will be entitled to receive a cash consideration of $37.00 for each Luminex share held.

The transaction is expected to close within the third quarter of 2021.

For additional information, please contact:

INVESTOR RELATIONS CONTACTS

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39 0161.487988
riccardo.fava@diasorin.it

Emanuela Salvini
Investor Relator
Tel: +39 0161.487567
emanuela.salvini@diasorin.it

U.S. MEDIA CONTACTS

Mary K. Conway
Tel: +1 516.606.6545
MConway@MKCStrategies.com

About DiaSorin
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.

For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The extensive diagnostic testing offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com